ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia

Differentiation therapies achieve remarkable success in acute promyelocytic leukemia, a subtype of acute myeloid leukemia (AML). However, excluding acute promyelocytic leukemia, clinical benefits of differentiation therapies in AML are negligible except for those targeting mutant isocitrate dehydrog...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Haematologica
Auteurs principaux: Zhou, Jianbiao, Quah, Jessie Yiying, Ng, Yvonne, Chooi, Jing-Yuan, Toh, Sabrina Hui-Min, Lin, Baohong, Tan, Tuan Zea, Hosoi, Hiroki, Osato, Motomi, Seet, Qihui, Ooi, A.G. Lisa, Lindmark, Bertil, McHale, Mark, Chng, Wee-Joo
Format: Artigo
Langue:Inglês
Publié: Fondazione Ferrata Storti 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7556493/
https://ncbi.nlm.nih.gov/pubmed/33054053
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2019.230482
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires